Gene Therapy Briefs

Abstract

Get full access to this article

View all access options for this article.

References

AveXis. AveXis announces New England Journal of Medicine publication of Phase 1 data of AVXS-101 gene replacement therapy in spinal muscular atrophy Type 1. http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle&ID=2313601 (last accessed November 17, 2017).

Mendell

, Al-Zaidy

, Shell

, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. New Engl J Med, 2017; 377:1713–1722.

Lewis

Gene therapy replaces boy's entire epidermis. https://www.medscape.com/viewarticle/888245 - vp_1 (last accessed November 17, 2017).

Mavilio

, Pellegrini

, Ferrari

, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med, 2006; 12:1397.

Hirsch

, Rothoeft

, Teig

, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature, 2017; 551:327–332.

Aragona

, Blanpain

. Commentary: transgenic stem cells replace skin. Nature, 2017; 551:306–307.

bluebird bio. bluebird bio announces publication of interim data from Starbeam Study of Lenti-D™ drug product in patients with cerebral adrenoleukodystrophy (CALD) in the New England Journal of Medicine. http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-publication-interim-data-starbeam-study (last accessed November 17, 2017).

Spark Therapeutics. FDA advisory committee unanimously recommends approval of investigational Luxturna™ (voretigene neparvovec) for patients with biallelic RPE65-mediated inherited retinal disease. http://ir.sparktx.com/news-releases/news-release-details/fda-advisory-committee-unanimously-recommends-approval (last accessed November 11, 2017).

Russell

, Bennett

, Wellman

, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, Phase 3 trial. Lancet, 2017; 390:849–860.

10.

Novartis. Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice. https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019 (last accessed November 15, 2017).

11.

Gilead Sciences. Kite's Yescarta™ (axicabtagene ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. www.gilead.com/news/press-releases/2017/10/kites-yescarta-axicabtagene-ciloleucel-becomes-first-car-t-therapy-approved-by-the-fda-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-large-bcell-lymphoma-after-two-or-more-lines-of-systemic-therapy (last accessed November 15, 2017).

12.

uniQure. uniQure announces hemophilia B gene therapy program to enter pivotal study with FIX-Padua cariant in 2018. https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3388861&lang=en-GB&companycode=nl-qure&v (last accessed November 16, 2017).

13.

National Institute for Health and Care Excellence. Evaluation consultation document Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency. https://www.nice.org.uk/guidance/GID-HST10005/documents/evaluation-consultation-document (last accessed November 15, 2017).

14.

Miller

. 2017. Gene therapy holds great promise, but big price. http://lab.express-scripts.com/lab/insights/drug-options/gene-therapy-holds-great-promise-but-big-price (last accessed November 11, 2017).

15.

Kolata

. 2017. New gene-therapy treatments will carry whopping price tags. The New York Times, September 11, 2017. https://www.nytimes.com/2017/09/11/health/cost-gene-therapy-drugs.html (last accessed November 11, 2017).

16.

Montazerhodjat

, Weinstock

, Lo

. Buying cures versus renting health: financing health care with consumer loans. Sci Transl Med, 2016; 8:327ps326.

17.

StreetInsider. Express Scripts (ESRX) CMO issues blog on CAR-Ts and gene therapies. https://www.streetinsider.com/Analyst+Comments/Express+Scripts+%28ESRX%29+CMO+Issues+Blog+on+CAR-Ts+and+Gene+Therapies/13318181.html (last accessed November 11, 2017).

18.

Ultragenyx Pharmaceutical. Ultragenyx completes tender offer and acquisition of Dimension Therapeutics. http://ir.ultragenyx.com/releasedetail.cfm?ReleaseID=1047500 (last accessed November 13, 2017).

19.

REGENXBIO. Regenxbio responds to notification of a superior proposal under its merger agreement with Dimension Therapeutics. http://globenewswire.com/news-release/2017/10/02/1138738/0/en/REGENXBIO-Responds-to-Notification-of-a-Superior-Proposal-Under-Its-Merger-Agreement-With-Dimension-Therapeutics.html?f=22&fvtc=7 (last accessed November 13, 2017).

20.

Voyager Therapeutics. Voyager Therapeutics announces update to Parkinson's disease program. http://ir.voyagertherapeutics.com/phoenix.zhtml?c=254026&p=irol-newsArticle&ID=2312537 (last accessed November 11, 2017).

21.

Voyager Therapeutics. Voyager Therapeutics announces positive results from ongoing Phase 1b trial of VY-AADC01 for advanced Parkinson's disease. http://ir.voyagertherapeutics.com/phoenix.zhtml?c=254026&p=irol-newsArticle&ID=2298649 (last accessed November 11, 2017).

22.

Voyager Therapeutics. Voyager Therapeutics reports third quarter 2017 financial results and corporate highlights. http://ir.voyagertherapeutics.com/phoenix.zhtml?c=254026&p=irol-newsArticle&ID=2313987 (last accessed November 11, 2017).

23.

Gilead Sciences. Gilead Sciences to acquire Kite Pharma for $11.9 billion. www.gilead.com/news/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion (last accessed November 13, 2017).